ArticleJournal of computer-aided molecular design2026
Multimodal computational approaches coupled with experimental assays to identify flavonoids as potent inhibitors of diabetes and AGEs.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoids are found in most edible plants and vegetables and due to their specialized chemical structures and biological activities, we aimed to investigate the efficacy of selected common flavonoids against diabetes-related advance glycation end products (AGEs) through both computational and experimental approaches. Major in silico techniques involved network pharmacology, molecular docking and in vitro AGEs inhibition assays. The pathway enrichment analysis revealed a significant association between AGE regulation and several key biological pathways, including those involved in phenylalanine metabolism, Th17 cell differentiation, and sphingolipid signaling. Molecular docking revealed that hesperidin exhibited the highest binding affinities with transcription regulators 3CJJ (ΔG - 7.1 kJ/mol) and 3TOP (ΔG - 10.0 kJ/mol), while epicatechin showed strong binding to 4F5S (ΔG - 8.3 kJ/mol). All tested compounds significantly reduced oxidative stress, with hesperidin demonstrating moderate inhibition of advanced glycation in the bovine serum albumin (BSA)-glucose model (61.2% ± 1.4%) and BSA-MGO model (52.1% ± 1.7%), as well as potent α-glucosidase inhibition (IC
Indexed as
Identifiers
41553552What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.